{"name":"Harmony Biosciences Holdings, Inc.","slug":"harmony-bio","ticker":"HRMY","exchange":"NASDAQ","domain":"harmonybiosciences.com","description":"Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fr","hq":"Plymouth Meeting, Pennsylvania","founded":2018,"employees":"293","ceo":"John C. Jacobs","sector":"Specialty Pharma","stockPrice":28.75,"stockChange":1.13,"stockChangePercent":4.09,"marketCap":"$1.7B","metrics":{"revenue":868452992,"revenueGrowth":21.1,"grossMargin":77.2,"rdSpend":0,"netIncome":158687008,"cash":775340032,"dividendYield":0,"peRatio":10.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"WAKIX patent cliff ($544.8M at risk)","drug":"WAKIX","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"The company reported revenue of $144.8 million for the fourth quarter and $544.8 million for the full year 2022.","drugName":"","sentiment":"neutral"},{"date":"2022-11-14","type":"deal","headline":"Harmony Biosciences Announces Collaboration with the National Sleep Foundation","summary":"The company partnered with the National Sleep Foundation to raise awareness about narcolepsy and other sleep disorders.","drugName":"","sentiment":"positive"},{"date":"2022-08-01","type":"regulatory","headline":"Harmony Biosciences Submits New Drug Application for JZP-258","summary":"The company submitted a New Drug Application to the FDA for JZP-258, a treatment for cataplexy in patients with narcolepsy.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFAxWXJobXFZM0lyNjdOTkpRNzBtS09BRklkMFgtakFRb1duUGx6YS1hSmdpa1JaYXVXYnJVM3NiYnZBbEJFY2hhWmo4OW9GQ1VsWXc?oc=5","date":"2026-04-05","type":"pipeline","source":"Yahoo Finance UK","summary":"Harmony Biosciences Holdings, Inc. (HRMY) stock price, news, quote and history - Yahoo Finance UK","headline":"Harmony Biosciences Holdings, Inc. (HRMY) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-04","type":"pipeline","source":"simplywall.st","summary":"How Investors May Respond To Harmony Biosciences (HRMY) Strengthening Its C-Suite And Board For Execution - simplywall.st","headline":"How Investors May Respond To Harmony Biosciences (HRMY) Strengthening Its C-Suite And Board For Execution","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-02","type":"pipeline","source":"simplywall.st","summary":"A Look At Harmony Biosciences Holdings (HRMY) Valuation After Recent Share Price Weakness - simplywall.st","headline":"A Look At Harmony Biosciences Holdings (HRMY) Valuation After Recent Share Price Weakness","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1FeWFXQUZqUERDelpUQXd6MjQxR2RaTjJWN1NkMFliQjNuY3JJUWkyZ2ZpSGFQeUR5ZTVYZ01VZWJmMWRiVV9YVWd5NXZ2SjZyY19OT0h6RzhOUWs1VkJkU1VyamZkdw?oc=5","date":"2026-03-14","type":"pipeline","source":"Stock Titan","summary":"HRMY SEC Filings - Harmony Biosciences Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan","headline":"HRMY SEC Filings - Harmony Biosciences Holdings, Inc. 10-K, 10-Q, 8-K Forms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQeW1EYXBJM2xkeDRvRFd6VFZscmFoMjRhc2dlY3RIYkp5T3ItNHJOM2c0cVBGdjBFTFQ3SmdSMjM0aExHbU02NnpmWDRQbWpqMXFSR0NQbTVSV3ZydE45dmZXTVcwa3J2ZzZYMUZzN1JGSHBuOTNfNUw2a0F1SFhxMFEtbGE1UQ?oc=5","date":"2026-02-28","type":"deal","source":"Insider Monkey","summary":"12 Cheap Biotech Stocks to Buy Now - Insider Monkey","headline":"12 Cheap Biotech Stocks to Buy Now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxOWmNYTGwxLTRic2lrbGh1M2V2RUpHX1JKM1JkRThJQjFaNGRwVEFjY2xhTGluVENsZWstb0FrZklfcldmTkk1aHlJTGpaNjRhS2ktX0NuRkw1N0VmNUZxVHFPc0ZMUHNLVS1xVkJ3RlFDYTQ1bTlZMjdaNFVUUnJ4bVl5SVZrZFhSQ0NOQlhzUURsaXNHbUYzN18zNF8wZkNLZUN3Yk5RTHNMZUJUdGF6XzVkc0hyZ25lYVBsUmJHQUJVU0VadHhNLTdPMy1kdmpOaktVQ2dPaGp5NVNzSlFOVVh0SWxrSm9kZFFXVmg3OFV6Zi1K0gH6AUFVX3lxTE55dEdvV3hvOE9vc2FMS1IwU3RaR1NZTHpKaVFDZUstVU1PZTJueWFVN0VQa29zbkNZMk5vOWxkUHh0cmZkc2lWcEZ5QlBZUnh6bXBpQ1VFT09NSkRmTGdkSVFYZzh2QUhrVDBQczh3STZCUlpnNm02QXlJZnYtdTNDT25Kc2VyRmpCd0cxTlhhb0I0RDBYYWhpbENBNXhqR2JjcnE2dXJMQnhiYmp3ckdNbUpuVktWOWszN2wyV2EzQmpjSkV3XzFSWUJYazRJS1dPSmFDTXZTRjBXajhySFJXZTVsNkJJQVNlSTVnRWxzTGtiY0p0N3VPbmc?oc=5","date":"2026-02-24","type":"pipeline","source":"simplywall.st","summary":"Is Harmony Biosciences (HRMY) Pricing Reflect Recent Share Slump And DCF Upside Potential - simplywall.st","headline":"Is Harmony Biosciences (HRMY) Pricing Reflect Recent Share Slump And DCF Upside Potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPbGxqVWM1ejVvU3pwV2hvLXVieXJHQVlTTWNDcW8ycGpNNThLMHFGd2xJQlpHYkptMmxrNW9sQ2Q4YVJPUG44SGx0NklDM0lpUDVkenVQQUFQYkp4VmpVeXlqY2hfZXNBOXFsbzI2OUZJX3pwNTdBOEd4RHFVc0J4bzRkbzNwZWdjSkJyOWJxRXZsQXhPaEVVWmlhN0VWTllxRVJLUFc5bkRnX1c0TEcyQ0hhNWZ5R1FhalY2M1NPbHFyNVpu?oc=5","date":"2026-02-23","type":"patent","source":"Investing.com","summary":"Deutsche Bank cuts Harmony Biosciences stock rating on patent risk - Investing.com","headline":"Deutsche Bank cuts Harmony Biosciences stock rating on patent risk","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQLUtESERjeWpNcGRfZ3JBbkp4aG9YRHh2Mkg4Sm1TeGNoUElGSEF0cWd6OEdSMWZ0eXJXbE9tS0wzZ3VPVG43VC1CUWVHLVVSbXM0R3NGSjZuZEsySVRweHJJSmpVcElJSDQtQzlabG05QUczcWtsRzMyNjdpdGVLTy1ULUdqdTZ3d0xSdXhWSQ?oc=5","date":"2026-02-01","type":"pipeline","source":"Intellectia AI","summary":"Harmony Biosciences CFO Fully Exits Equity Ownership - Intellectia AI","headline":"Harmony Biosciences CFO Fully Exits Equity Ownership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPUm1CMUtQcVZsVWQwZ1FQaHJ2Y0kxYnNVaEt3U3NoLXNGbG1HMVBNV19tOXJZZ0pxMy1SSG4zWTdFYmtjSGFKdU9Zejg4eWdOS3AtTUEtaXpuWk5mWHRzVGpBLVVyN3ZvN3I1X1hLZDBWWm1sS1RGMXFjTTg5THk2a2RhV2s2RkNGQkhvOXMxMGRSaFJLNEM0OS0waWM3ZnZQLWhhQUt1QVpZQTJKNGc?oc=5","date":"2026-01-27","type":"earnings","source":"Finviz","summary":"Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? - Finviz","headline":"Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQQXZxRXRoY2hsMWZVQllLQXE3cEg3d2F5TlF5alpJcEpoWW8xaE1Lc3JaLVRfa0FvcEtVTjJsOVpZQTQtWXVPZ3hmTDhoRm9MeS1BdEhkakp4Z2VhRk0yRm9CZll3aWEwSlVnOTFvVlpLa0hoVzJ4TVRSMTZBcllRYWpJbk9CMXAzdU45aGtDY3d6V1dkSXVpMXI3Tl85bWVxNW5nejBWbnVfdVhUbXhXVg?oc=5","date":"2025-09-25","type":"pipeline","source":"Seeking Alpha","summary":"Harmony Biosciences: Cannabinoid Fragile X Fail Merits Rating Downgrade (NASDAQ:HRMY) - Seeking Alpha","headline":"Harmony Biosciences: Cannabinoid Fragile X Fail Merits Rating Downgrade (NASDAQ:HRMY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOaWN0bVZtdzRqMTJ1OFYzbGgwS0s4UXZBMU9Wdzk3eWNGalJlRkF6czE5dXZRa0NjZHJabnFVcy15X0E2WnhBM1IxZDlHWGVNc3dfMUViRHRaMENGa21remloXzYydVhnZ214M2xsS2E0UmRMZzRNck0ya0JXa2hZNFBqdTI?oc=5","date":"2025-09-17","type":"deal","source":"Yahoo Finance","summary":"UBS Maintains a Buy Rating on Harmony Biosciences Holdings (HRMY), Sets a $50 PT - Yahoo Finance","headline":"UBS Maintains a Buy Rating on Harmony Biosciences Holdings (HRMY), Sets a $50 PT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPaFJ3d1lpSFRJYlFnNXBETHZ2M29ianVMV1hWRnlKUjY5a3pXc0tpVGxGR2hHUkY3bm94clNEZjY2TWFoRjIyZS0tTnEtNllMeEhKanRPSmVVS3pHWHl5akE1T1BQR09LLTdneWtxdHFnUWpzUXVIcDRVaW8yU3BEOTM5ZjVrRWI5TjFmSUNqM25mVzJ4blZmZ0ZfSDVlRnRJdG93dHc0OG9Gbm1iZ1BWSVBkS21oa1dIUXRqMDlMY3ZjV2k5aUtXR3FwVkJCWmY2bkJTaUlnZnFsTWN5VlE?oc=5","date":"2023-10-11","type":"pipeline","source":"PR Newswire","summary":"HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE - PR Newswire","headline":"HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE","sentiment":"neutral"}],"patents":[{"drugName":"WAKIX","drugSlug":"pitolisant","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":544800000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Spectrum Pharmaceuticals","Aquestive Therapeutics","Ultragenyx Pharmaceutical"],"therapeuticFocus":["Neurology","Neurodegenerative Diseases"],"financials":null,"yahoo":{"currentPrice":28.75,"previousClose":27.62,"fiftyTwoWeekHigh":40.87,"fiftyTwoWeekLow":25.52,"fiftyTwoWeekRange":"25.52 - 40.87","fiftyDayAverage":31.33,"twoHundredDayAverage":33.24,"beta":0.89,"enterpriseValue":991465728,"forwardPE":5,"priceToBook":1.91,"priceToSales":1.92,"enterpriseToRevenue":1.14,"enterpriseToEbitda":4.24,"pegRatio":0,"ebitda":233804000,"ebitdaMargin":26.9,"freeCashflow":211456496,"operatingCashflow":348199008,"totalDebt":169248000,"debtToEquity":19.4,"currentRatio":3.6,"returnOnAssets":11.5,"returnOnEquity":20.8,"analystRating":"","recommendationKey":"none","numberOfAnalysts":11,"targetMeanPrice":42,"targetHighPrice":62,"targetLowPrice":25,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":12.1,"institutionHeldPercent":91.1,"sharesOutstanding":57867389,"floatShares":50902054,"sharesShort":7622382,"shortRatio":5.62,"shortPercentOfFloat":13.2,"epsTrailing":2.71,"epsForward":5.79,"revenuePerShare":15.11,"bookValue":15.07,"officers":[{"age":57,"name":"Mr. Jeffrey S. Aronin","title":"Founder & Non-Executive Chairman"},{"age":68,"name":"Dr. Jeffrey M. Dayno M.D.","title":"President, CEO & Director"},{"age":55,"name":"Mr. Peter  Anastasiou","title":"Chief Operating Officer"},{"age":54,"name":"Dr. Kumar  Budur M.D., M.S.","title":"Executive VP and Chief Medical & Scientific Officer"},{"age":50,"name":"Mr. Andrew  Serafin J.D., M.B.A.","title":"Executive VP & Chief Strategy Officer"},{"age":null,"name":"Brennan  Doyle","title":"VP & Head of Investor Relations"},{"age":null,"name":"Mr. Christian  Ulrich J.D.","title":"Executive VP, General Counsel & Corporate Secretary"},{"age":null,"name":"Ms. Tricia  Glover","title":"Chief Compliance Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.harmonybiosciences.com","phone":"484 539 9800"}}